Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial
- PMID: 16418786
- DOI: 10.1359/JBMR.051015
Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial
Abstract
A 3-year, randomized, double-blind, placebo-controlled trial evaluated the effect of oral alendronate on the BMD of 64 adult patients with osteogenesis imperfecta. The mean increases in the lumbar spine BMD were 10.1 +/- 9.8% (p < 0.001) and 0.7 +/- 5.7% in the alendronate and placebo groups, respectively. Oral alendronate increases BMD in adult patients with osteogenesis imperfecta.
Introduction: This study evaluated the effect of oral alendronate on the BMD of adult patients with osteogenesis imperfecta.
Materials and methods: We carried out a 3-year, randomized, double-blind, placebo-controlled trial of oral alendronate in 64 adult patients with osteogenesis imperfecta. The primary endpoint was the difference between the groups in the mean percent change in lumbar spine BMD at 3 years. Secondary outcomes included changes in BMD of total hip, vertebral and peripheral fracture incidence, pain, hearing loss, and bone turnover biochemical markers. Patients were treated daily with either placebo or 10 mg alendronate. All received 1 g of calcium and 800 IU of vitamin D daily.
Results: The mean +/- SD increases in the lumbar spine BMD were 10.1 +/- 9.8% (p < 0.001) and 0.7 +/- 5.7% in the alendronate and placebo groups, respectively. Hip BMD increased in the alendronate group by 3.3 +/- 0.5% (p = 0.001) and decreased in the placebo group by 0.3 +/- 0.6%. The sample size was not sufficient to determine an effect of alendronate on fracture rate. A significant increase of the pain score was noted in the alendronate group (p = 0.04) in the intent-to-treat analysis but not in the per protocol analysis. There was no change in hearing in either group. Bone resorption and formation biochemical markers were significantly decreased in the alendronate group (p < 0.001). There were no differences in severe adverse effects between the groups, but there was an increase in nonsevere upper gastrointestinal effects in the alendronate group (p = 0.003).
Conclusions: Oral alendronate increases BMD and increase nonsevere gastrointestinal adverse effects but does not modify the hearing loss in adult patients with osteogenesis imperfecta. More studies are needed to evaluate an effect on the fracture rate.
Similar articles
-
A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study.Eur Urol. 2013 May;63(5):927-35. doi: 10.1016/j.eururo.2012.09.007. Epub 2012 Sep 11. Eur Urol. 2013. PMID: 23040208 Clinical Trial.
-
Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.Osteoporos Int. 2006;17(5):716-23. doi: 10.1007/s00198-005-0037-2. Epub 2006 Feb 3. Osteoporos Int. 2006. PMID: 16463007 Clinical Trial.
-
Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta.J Bone Miner Res. 2006 Jan;21(1):132-40. doi: 10.1359/JBMR.051006. Epub 2005 Oct 17. J Bone Miner Res. 2006. PMID: 16355282 Clinical Trial.
-
Bisphosphonate therapy for osteogenesis imperfecta.Cochrane Database Syst Rev. 2014 Jul 23;(7):CD005088. doi: 10.1002/14651858.CD005088.pub3. Cochrane Database Syst Rev. 2014. Update in: Cochrane Database Syst Rev. 2016 Oct 19;10:CD005088. doi: 10.1002/14651858.CD005088.pub4. PMID: 25054949 Updated. Review.
-
Bisphosphonate therapy for osteogenesis imperfecta.Cochrane Database Syst Rev. 2016 Oct 19;10(10):CD005088. doi: 10.1002/14651858.CD005088.pub4. Cochrane Database Syst Rev. 2016. PMID: 27760454 Free PMC article. Review.
Cited by
-
Current and Developing Pharmacologic Agents for Improving Skeletal Health in Adults with Osteogenesis Imperfecta.Calcif Tissue Int. 2024 Mar 12. doi: 10.1007/s00223-024-01188-2. Online ahead of print. Calcif Tissue Int. 2024. PMID: 38472351 Review.
-
Efficacy and Safety of Denosumab vs Zoledronic Acid in OI Adults: A Prospective, Open-Label, Randomized Study.J Clin Endocrinol Metab. 2024 Jun 17;109(7):1873-1882. doi: 10.1210/clinem/dgae012. J Clin Endocrinol Metab. 2024. PMID: 38181430 Free PMC article. Clinical Trial.
-
Tensile Mechanical Properties of Dry Cortical Bone Extracellular Matrix: A Comparison Among Two Osteogenesis Imperfecta and One Healthy Control Iliac Crest Biopsies.JBMR Plus. 2023 Oct 11;7(12):e10826. doi: 10.1002/jbm4.10826. eCollection 2023 Dec. JBMR Plus. 2023. PMID: 38130764 Free PMC article.
-
The patient clinical journey and socioeconomic impact of osteogenesis imperfecta: a systematic scoping review.Orphanet J Rare Dis. 2023 Feb 22;18(1):34. doi: 10.1186/s13023-023-02627-3. Orphanet J Rare Dis. 2023. PMID: 36814274 Free PMC article. Review.
-
Approach to the Patient: Pharmacological Therapies for Fracture Risk Reduction in Adults With Osteogenesis Imperfecta.J Clin Endocrinol Metab. 2023 Jun 16;108(7):1787-1796. doi: 10.1210/clinem/dgad035. J Clin Endocrinol Metab. 2023. PMID: 36658750 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical

